When is protein binding important?

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3458-3467

  Heuberger, Jules ^a   Schmidt, Stephan ^a   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Drug interaction; in vitro models; in vitro in vivo correlations (IVIVC); Microdialysis; Pharmacokinetics; Protein binding

Indexed keywords

ALBUMIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLOBAZAM; FLUNITRAZEPAM; MIDAZOLAM; OXAZEPAM; PHENYTOIN; QUINOLONE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG INTERACTION; DRUG ISOLATION; DRUG METABOLISM; DRUG MONITORING; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; LIVER CLEARANCE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PLASMA PROTEIN BINDING; PROTEIN BINDING; RECEPTOR AFFINITY; RECEPTOR BINDING; STEADY STATE;

DRUG INTERACTION; IN VITRO MODELS; IN VITRO/IN VIVO CORRELATIONS (IVIVC); MICRODIALYSIS; PHARMACOKINETICS; PROTEIN BINDING;

ALGORITHMS; BLOOD PROTEINS; DRUG DISCOVERY; HUMANS; INFUSIONS, PARENTERAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGICAL PROCESSES; PROTEIN BINDING;

EID: 84881615325     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23559     Document Type: Article

References (48)

1. Benet LZ, Hoener BA. 2002. Changes in plasma protein binding have little clinical relevance. Clin Pharm Ther 71(3):115-121.
2. Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. 1967. Potentiation of anticoagulant effect of warfarin by phenylbutazone. New Engl J Med 276(9):496-501.
3. MacKichan JJ. 1989. Protein binding drug displacement interactions fact or fiction? Clin Pharm 16(2):65-73.
4. Rolan PE. 1994. Plasma protein binding displacement interactions-Why are they still regarded as clinically important? Brit J Clin Pharm 37(2):125-128.
5. Sansom LN, Evans AM. 1995. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 12(4):227-233.
6. Derendorf H. 2007. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharm 47(6):782-789.
7. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. 2006. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Resp J 28(5):1042-1050.
8. Meltzer EO, Derendorf H. 2006. The systemic safety of inhaled corticosteroid therapy: A focus on ciclesonide. Ann Allergy Asthma Immunol 97(2):149-157.
9. Skoner DP, Maspero J, Banerji D, Ciclesonide Pediatric Growth Study G. 2008. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 121(1):e1-14.
10. Schmidt S, Gonzalez D, Derendorf H. 2010. Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99(3):1107-1122.
11. Craig WA. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17(3):479-501.
12. Gonzalez D, Schmidt S, Derendorf H. 2013. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev 26:274-288.
13. Kunin CM. 1967. Clinical significance of protein binding of the penicillins. Ann NY Acad Sci 145(2):282-290.
14. Winter ME. 2004. Basic clinical pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams & Wilkins.
15. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. 2011. Protein binding: Do we ever learn? Antimicrob Agents Chemother 55(7):3067-3074.
16. Lee BL, Sachdeva M, Chambers HF. 1991. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother 35(12):2505-2508.
17. Craig WA, Welling PG. 1977. Protein binding of antimicrobials: Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2(4):252-268.
18. Zeitlinger MA, Sauermann R, Traunmuller F, Georgopoulos A, Muller M, Joukhadar C. 2004. Impact of plasma protein binding on antimicrobial activity using time-killing curves. J Antimicrob Chemother 54(5):876-880.
19. Tawara S, Matsumoto S, Kamimura T, Goto S. 1992. Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics. Antimicrob Agents Chemother 36(1):17-24.
20. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother 55(5):601-607.
21. Mandema JW, Sansom LN, Dios-Vieitez MC, Hollander-Jansen M, Danhof M. 1991. Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. J Pharmacol Exp Ther 257(1):472-478.
22. Kunin CM, Craig WA, Kornguth M, Monson R. 1973. Influence of binding on the pharmacologic activity of antibiotics. Ann NY Acad Sci 226:214-224.
23. Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT, Derendorf H. 2008. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother 52(11):3994-4000.
24. Nix DE, Matthias KR, Ferguson EC. 2004. Effect of ertapenem protein binding on killing of bacteria. Antimicrob Agents Chemother 48(9):3419-3424.
25. Riley RJ, Grime K. 2004. Metabolic screening in vitro: Metabolic stability, CYP inhibition and induction. Drug Discov Today: Technol 1(4):365-372.
26. Faed EM. 1981. Protein binding of drugs in plasma, interstitial fluid and tissues: Effect on pharmacokinetics. Eur J Clin Pharmacol 21(1):77-81.
27. Gillette JR. 1971. Factors affecting drug metabolism. Ann NY Acad Sci 179:43-66.
28. US FDA. 2012. FDA Guidance for industry. Drug interaction studies-Study design, data analysis, implications for dosing, and labeling recommendations.
29. EMA. 2012. EMA guideline on the investigation of drug interactions.
30. Rane A, Wilkinson GR, Shand DG. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200(2):420-424.
31. Obach RS. 1996. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab Dispos 24(10):1047-1049.
32. Obach RS. 1997. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25(12):1359-1369.
33. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27(11):1350-1359.
34. Kalvass JC, Tess DA, Giragossian C, Linhares MC, Maurer TS. 2001. Influence of microsomal concentration on apparent intrinsic clearance: Implications for scaling in vitro data. Drug Metab Dispos 29(10):1332-1336.
35. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33(9):1304-1311.
36. Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ. 2002. Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30(12):1441-1445.
37. Margolis JM, Obach RS. 2003. Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: Implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31(5):606-611.
38. Brown HS, Galetin A, Hallifax D, Houston JB. 2006. Prediction of in vivo drug-drug interactions from in vitro data: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 45(10):1035-1050.
39. McLure JA, Miners JO, Birkett DJ. 2000. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 49(5):453-461.
40. Gao H, Yao L, Mathieu HW, Zhang Y, Maurer TS, Troutman MD, Scott DO, Ruggeri RB, Lin J. 2008. In silico modeling of nonspecific binding to human liver microsomes. Drug Metab Dispos 36(10):2130-2135.
41. Poulin P, Haddad S. 2011. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J Pharm Sci. [Epub ahead of print.]
42. De Buck SS, Sinha VK, Fenu LA, Gilissen RA, Mackie CE, Nijsen MJ. 2007. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Dispos 35(4):649-659.
43. Fagerholm U. 2007. Prediction of human pharmacokinetics-Evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 59(6):803-828.
44. Grime K, Riley RJ. 2006. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Curr Drug Metab 7(3):251-264.
45. Poulin P, Kenny JR, Hop CE, Haddad S. 2012. In vitro-in vivo extrapolation of clearance: Modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J Pharm Sci 101(2):838-851.
46. Berezhkovskiy LM. 2011. The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionization in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J Pharm Sci 100(3):1167-1183.
47. Poulin P, Hop CE, Ho Q, Halladay JS, Haddad S, Kenny JR. 2012. Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 101(11):4308-4326.
48. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS. 2009. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction. Drug Metab Dispos 37(8):1658-1666.